Researchers at Duke Health studied more than 230 patients treated with lecanemab, a new FDA-approved therapy (known as an anti-amyloid therapy) designed to remove a protein linked to Alzheimer's disease from the brain. They found the therapy's real-world safety, treatment persistence, and effects on disease progession aligned with results from clinical trials - including the most closely watched side effect, which involves brain swelling or bleeding, commonly referred to as Amyloid Related Imaging Abnormalities (ARIA).